---
company: Longeveron Inc.
ticker: LGVN
form: 8-K
filed: 2026-05-13
accession: 0001213900-26-055806
source: https://www.sec.gov/Archives/edgar/data/1721484/000121390026055806/
---

# Longeveron (LGVN) earnings release, May 13, 2026

Longeveron Inc. (LGVN) · Form 8-K, Item 2.02 · Filed 2026-05-13 · [SEC filing](https://www.sec.gov/Archives/edgar/data/1721484/000121390026055806/)

Longeveron Announces 2026 First Quarter Financial

Results and Provides Business Update

MIAMI, Fla., May 13, 2026 -- Longeveron Inc. (NASDAQ:

LGVN), a clinical stage biotechnology company developing cellular therapy for life-threatening, rare pediatric and chronic aging-related conditions, today reported financial results for the quarter ended March 31, 2026 and provided a business update.

“Earlier this year, we initiated a strategic repositioning of Longeveron designed to maximize shareholder value while maintaining disciplined capital allocation,” said Stephen

H. Willard, Chief Executive Officer of Longeveron. “We have transitioned toward a more capital-efficient, asset-light operating model, with an increased focus on securing strategic licensing partnerships for our stem cell therapy laromestrocel in four development programs. Longeveron is approaching a series of potentially transformative milestones across these programs that have the potential to redefine the trajectory of our business, with the first catalyst, top line results from our Phase 2b clinical trial in HLHS, anticipated in August of this year.”

Development Programs

Longeveron’s investigational therapeutic candidate laromestrocel (Lomecel-B®) is a proprietary, scalable, allogeneic cellular therapy being evaluated in multiple indications.

Hypoplastic Left Heart Syndrome (HLHS) – a rare pediatric congenital heart birth defect in which the left ventricle (one of the pumping chambers of the heart) is either severely underdeveloped or missing.

Alzheimer’s disease (AD) – a neurodegenerative disorder that leads to progressive memory loss and death and currently has very limited therapeutic options.

Pediatric Dilated Cardiomyopathy (PDCM) – a rare pediatric cardiovascular disease in which the muscles in one or more of the heart chambers become enlarged or stretched

(dilated), with nearly 40% of children with PDCM requiring a heart transplant or dying within two years of diagnosis.

Partnering Strategy

Laromestrocel represents a pipeline in a product opportunity that has delivered positive initial results from multiple clinical trials across several indications. Our stem cell therapy development programs address life-threatening conditions in the most vulnerable populations - children and the elderly: Hypoplastic Left

Heart Syndrome; Alzheimer’s disease; Pediatric Dilated Cardiomyopathy and Aging-related Frailty (AF). These four initial indications address market opportunities of what we estimate to be approximately ~$1 billion, ~$5+ billion, up to ~$1 billion, and ~$4 billion, respectively.

We plan to pursue a robust partnering strategy across our development programs to accelerate potential time to market, increase capital use efficiency and leverage the greater resources of larger organizations.²

Longeveron will participate in the BIO International

Convention taking place June 22-25, 2026 at the San Diego Convention Center. Stephen Willard, CEO, Dr. Joshua Hare, Founder, CSO and Executive

Chairman, and Than Powell, Business Development, will host meetings with global pharmaceutical company executives to explore potential partnership and strategic opportunities for the Company’s four stem cell development programs.

First Quarter Corporate Updates

2026 First Quarter Summary Financial Results

Related cost of revenues was $0.1 million in each of the three months ended March 31, 2026 and 2025. This resulted in a gross profit of $0.3 million in each of the three months ended March 31, 2026 and 2025.³

Conference Call and Webcast Details:

An archived replay of the webcast will be available on the “Events & Presentations” section of the Company’s website following the conference.

About Longeveron Inc.

Longeveron is a clinical stage biotechnology company developing regenerative medicines to address unmet medical needs. The Company’s lead investigational product is laromestrocel

(Lomecel-B

TM), an allogeneic mesenchymal stem cell (MSC) therapy product isolated from the bone marrow of young, healthy adult donors. Laromestrocel has multiple potential mechanisms of action encompassing pro-vascular, pro-regenerative, anti-inflammatory, and tissue repair and healing effects with broad potential applications across a spectrum of disease areas. Longeveron is pursuing four pipeline indications: hypoplastic left heart syndrome (HLHS), Alzheimer’s disease, Pediatric Dilated Cardiomyopathy (DCM) and Aging-related

Frailty. Laromestrocel development programs have received five distinct and important FDA designations: for the HLHS program - Orphan

Drug designation, Fast Track designation, and Rare Pediatric Disease designation; and, for the AD program - Regenerative Medicine Advanced

Therapy (RMAT) designation and Fast Track designation. For more information, visit www.longeveron.com or follow Longeveron on LinkedIn,

X, and Instagram.⁴

Forward-Looking Statements

Certain statements in this press release that are not historical facts are forward-looking statements made pursuant to the safe harbor provisions of the Private Securities Litigation

Reform Act of 1995, which reflect management’s current expectations, assumptions, and estimates of future operations, performance and economic conditions, and involve known and unknown risks, uncertainties, and other important factors that could cause actual results, performance, or achievements to differ materially from those anticipated, expressed, or implied by the statements made herein. Forward-looking statements are generally identifiable by the use of forward-looking terminology such as “anticipate,” “believe,”

“contemplate,” “continue,” “could,” “estimate,” “expects,” “intend,”

“looks to,” “may,” “on condition,” “plan,” “potential,” “predict,”... (truncated“project,” “see,” “should,” “target,” “will,” “would,” or the negative thereof or comparable terminology, although not all forward-looking statements contain these words, or by discussion of strategy or goals or other future events, circumstances, or effects. Factors that could cause actual results to differ materially from those expressed or implied in any forward-looking statements in this release include, but are not limited to, the ability of our clinical trials to demonstrate safety and efficacy of our product candidates, and other positive results; our ability to successfully transition toward a more capital-efficient, asset-light operating model; our ability to secure one or more strategic licensing partnerships for our stem cell therapy laromestrocel in our development programs; the ability to reach alignment with the FDA on a potential path toward regulatory approval; receipt of trial results and other available evidence sufficient to support the Company filing a BLA following the readout of top-line results of the ELPIS II data; the timing and focus of our ongoing and future preclinical studies and clinical trials, and the reporting of data from those studies and trials;; market and other conditions, our cash position and need to raise additional capital, the difficulties we may face in obtaining access to capital, and the dilutive impact it may have on our investors; our financial performance, and ability to continue as a going concern; the period over which we estimate our existing cash and cash equivalents will be sufficient to fund our future operating expenses and capital expenditure requirements; the ability of our clinical trials to demonstrate safety and efficacy of our investigational product candidates, and other positive results; the timing and focus of our ongoing and future preclinical studies and clinical trials, and the reporting of data from those studies and trials; the size of the market opportunity for certain of our investigational product candidates, including our estimates of the number of patients who suffer from the diseases we are targeting; our ability to scale production and commercialize the investigational product candidate for certain indications; the success of competing therapies that are or may become available; the beneficial characteristics, safety, efficacy and therapeutic effects of our investigational product candidates; our ability to obtain and maintain regulatory approval of our investigational product candidates in the U.S. and other jurisdictions; our plans relating to the further development of our investigational product candidates, including additional disease states or indications we may pursue; our plans and ability to obtain or protect intellectual property rights, including extensions of existing patent terms where available and our ability to avoid infringing the intellectual property rights of others; the need to hire additional personnel and our ability to attract and retain such personnel; and our estimates regarding expenses, future revenue, capital requirements and needs for additional financing.

Further information relating to factors that may impact the Company’s results and forward-looking statements are disclosed in the Company’s filings with the Securities and

Exchange Commission, including Longeveron’s Annual Report on Form 10-K for the year ended December 31, 2025, filed with the Securities and Exchange Commission on March 17, 2026, its Quarterly Reports on Form 10-Q, and its Current Reports on Form 8-K. The Company operates in highly competitive and rapidly changing environment; therefore, new factors may arise, and it is not possible for the Company’s management to predict all such factors that may arise nor assess the impact of such factors or the extent to which any individual factor or combination thereof, may cause results to differ materially from those contained in any forward-looking statements. The forward-looking statements contained in this press release are made as of the date of this press release based on information available as of the date of this press release, are inherently uncertain, and the Company disclaims any intention or obligation, other than imposed by law, to update or revise any forward-looking statements, whether as a result of new information, future events, or otherwise.

Investor and Media Contact:

Derek Cole

Investor Relations Advisory Solutions derek.cole@iradvisory.com

---tables follow---⁵

Longeveron Inc.

Balance Sheets

(In thousands, except share and per share data)

See accompanying notes to financial statements.⁶

Longeveron Inc.

Statements of Operations

(In thousands, except per share data)

(Unaudited)

See accompanying notes to financial statements.⁷

## Financial statements

### Income Statement (Three months ended March 31, — (Unaudited) (in thousands))

| | Three months ended March 31, – 2026 | Three months ended March 31, – 2025 |
|---|---:|---:|
| Revenues | Clinical trial revenue | 378 | 259 |
| Revenues | Contract manufacturing lease revenue |  | 6 |
| Revenues | Contract manufacturing revenue | 20 | 116 |
| Revenues | Total revenues | 398 | 381 |
| Revenues | Cost of revenues | 134 | 106 |
| Revenues | Gross profit | 264 | 275 |
| Operating expenses | General and administrative | 2,720 | 2,941 |
| Operating expenses | Research and development | 2,319 | 2,515 |
| Operating expenses | Total operating expenses | 5,039 | 5,456 |
| Operating expenses | Loss from operations | -4,775 | -5,181 |
| Other income | Other income, net | 39 | 170 |
| Other income | Total other income, net | 39 | 170 |
| Other income | Net loss | -4,736 | -5,011 |
| Other income | Basic and diluted net loss per share | -0.19 | -0.34 |
| Other income | Basic and diluted weighted average common shares outstanding | 24,786,282 | 14,950,734 |

### Balance Sheet (March 31, 2026 — (In thousands, except share and per share data))

| | March 31, 2026 – (Unaudited) | December 31, 2025 |
|---|---:|---:|
| Current assets: | Cash and cash equivalents | 15,758 | 4,661 |
| Current assets: | Prepaid expenses and other current assets | 1,029 | 686 |
| Current assets: | Accounts receivable | 68 | 104 |
| Current assets: | Total current assets | 16,855 | 5,451 |
| Current assets: | Property and equipment, net | 1,651 | 1,836 |
| Current assets: | Intangible assets, net | 2,238 | 2,285 |
| Current assets: | Operating lease asset, net | 448 | 513 |
| Current assets: | Other assets | 18 | 176 |
| Current assets: | Total assets | 21,210 | 10,261 |
| Current liabilities: | Accounts payable | 293 | 423 |
| Current liabilities: | Accrued expenses | 2,921 | 2,969 |
| Current liabilities: | Current portion of lease liability | 688 | 655 |
| Current liabilities: | Deferred revenue | 102 | 40 |
| Current liabilities: | Other current liabilities | 341 |  |
| Current liabilities: | Total current liabilities | 4,345 | 4,087 |
| Long-term liabilities: | Long-term portion of operating lease liability | 60 | 169 |
| Long-term liabilities: | Liability related to the sale of future PRV proceeds | 778 |  |
| Long-term liabilities: | Other liabilities |  | 330 |
| Long-term liabilities: | Total long-term liabilities | 838 | 499 |
| Long-term liabilities: | Total liabilities | 5,183 | 4,586 |
| Stockholders’ equity: | Class A common stock, $0.001 par value per share, 84,295,000 shares authorized, 29,296,386 shares issued and outstanding at March 31, 2026; 21,445,336 issued and outstanding at December 31, 2025 | 29 | 21 |
| Stockholders’ equity: | Class B common stock, $0.001 par value per share, 15,705,000 shares authorized, 1,484,005 shares issued and outstanding at March 31, 2026, and December 31, 2025 | 1 | 1 |
| Stockholders’ equity: | Additional paid-in capital | 153,044 | 137,964 |
| Stockholders’ equity: | Accumulated deficit | -137,047 | -132,311 |
| Stockholders’ equity: | Total stockholders’ equity | 16,027 | 5,675 |
| Stockholders’ equity: | Total liabilities and stockholders’ equity | 21,210 | 10,261 |
